NCT06885424View on ClinicalTrials.gov

A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products

Enrolling by invitationOBSERVATIONAL
Enrollment

400

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

March 31, 2030

Study Completion Date

March 31, 2040

Conditions
Solid Tumor CancerSolid Tumor, Unspecified, AdultColorectal CarcinomaColorectal Carcinoma (CRC)Non Small Cell Lung CancerSmall Cell Lung Cancer ( SCLC )Pancreatic CancerNSCLCMesotheliomaOvarian CancerOvarian CarcinomaHead and Neck (HNSCC)Head and Neck CancerRenal Cell Carcinoma (Kidney Cancer)Triple Negative Breast Cancer (TNBC)
Interventions
OTHER

No additional intervention administered in this long term follow-up study

Safety follow-up for A2 Bio GT products administered in a previous interventional study

Trial Locations (2)

10016

NYU Langone Medical Center, New York

55905

Mayo Clinic, Rochester

Sponsors
All Listed Sponsors
lead

A2 Biotherapeutics Inc.

INDUSTRY